S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
Log in

Selecta Biosciences Stock Forecast, Price & News

-0.09 (-2.37 %)
(As of 03/8/2021 12:00 AM ET)
Today's Range
Now: $3.70
50-Day Range
MA: $4.28
52-Week Range
Now: $3.70
Volume1.45 million shs
Average Volume2.21 million shs
Market Capitalization$399.71 million
P/E RatioN/A
Dividend YieldN/A
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that has completed Phase II clinical trials for the treatment of chronic refractory gout. It also engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; BIND Therapeutics, Inc.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.
Selecta Biosciences logo


Selecta: ImmTOR Platform's Potential In Key
December 26, 2020 |  seekingalpha.com
Is SELB A Good Stock To Buy Now?
December 16, 2020 |  finance.yahoo.com
Selecta's (SELB) Gene Therapy Gets Orphan Drug Tag From FDA
November 20, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SELB
Year FoundedN/A



Sales & Book Value

Annual Sales$6.68 million
Book Value$0.10 per share


Net Income$-55,350,000.00


Market Cap$399.71 million
Next Earnings Date3/11/2021 (Confirmed)


Overall MarketRank

1.57 out of 5 stars

Medical Sector

392nd out of 1,971 stocks

Pharmaceutical Preparations Industry

191st out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
-0.09 (-2.37 %)
(As of 03/8/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SELB News and Ratings via Email

Sign-up to receive the latest news and ratings for SELB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions

Is Selecta Biosciences a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Selecta Biosciences stock.
View analyst ratings for Selecta Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Selecta Biosciences?

Wall Street analysts have given Selecta Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Selecta Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Selecta Biosciences' next earnings date?

Selecta Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Selecta Biosciences

How can I listen to Selecta Biosciences' earnings call?

Selecta Biosciences will be holding an earnings conference call on Thursday, March 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences, Inc. (NASDAQ:SELB) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by $0.57.
View Selecta Biosciences' earnings history

How has Selecta Biosciences' stock been impacted by COVID-19?

Selecta Biosciences' stock was trading at $3.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SELB shares have increased by 19.7% and is now trading at $3.70.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SELB?

7 brokers have issued 12-month price objectives for Selecta Biosciences' stock. Their forecasts range from $4.00 to $13.00. On average, they anticipate Selecta Biosciences' stock price to reach $7.20 in the next twelve months. This suggests a possible upside of 94.6% from the stock's current price.
View analysts' price targets for Selecta Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Selecta Biosciences' key executives?

Selecta Biosciences' management team includes the following people:
  • Dr. Carsten Brunn, CEO, Pres & Director (Age 50, Pay $942.52k)
  • Dr. Ulrich H. von Andrian-Werburg M.D., Ph.D., Co-Founder and Co-Chair of the Scientific Advisory Board
  • Mr. Bradford D. Dahms, CFO, Principal Financial Officer & Principal Accounting Officer (Age 33)
  • Dr. Lloyd Johnston, COO and Sr. VP of R&D (Age 53)
  • Dr. Takashi Kei Kishimoto, Chief Scientific Officer (Age 61)
  • Ms. Lynn Sanglier, VP of HR
  • Dr. Horacio Plotkin, Head of Clinical Devel. (Age 56)
  • Dr. Peter G. Traber, Chief Medical Officer (Age 66)
  • Ms. Ann K. Donohue, Controller

Who are some of Selecta Biosciences' key competitors?

What other stocks do shareholders of Selecta Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD).

When did Selecta Biosciences IPO?

(SELB) raised $64 million in an initial public offering (IPO) on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

What is Selecta Biosciences' stock symbol?

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Who are Selecta Biosciences' major shareholders?

Selecta Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.07%), Armistice Capital LLC (1.51%), Morgan Stanley (1.22%), JPMorgan Chase & Co. (0.92%), Endurant Capital Management LP (0.92%) and Renaissance Technologies LLC (0.90%). Company insiders that own Selecta Biosciences stock include Carsten Brunn, Peter G Traber, Timothy A Springer and Timothy C Barabe.
View institutional ownership trends for Selecta Biosciences

Which major investors are selling Selecta Biosciences stock?

SELB stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Endurant Capital Management LP, Alliancebernstein L.P., Wells Fargo & Company MN, New York State Common Retirement Fund, Virtus ETF Advisers LLC, Barclays PLC, and Northern Trust Corp.
View insider buying and selling activity for Selecta Biosciences
or view top insider-selling stocks.

Which major investors are buying Selecta Biosciences stock?

SELB stock was bought by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Morgan Stanley, BlackRock Inc., JPMorgan Chase & Co., Renaissance Technologies LLC, CM Management LLC, Cetera Advisors LLC, and Nuveen Asset Management LLC. Company insiders that have bought Selecta Biosciences stock in the last two years include Peter G Traber, Timothy A Springer, and Timothy C Barabe.
View insider buying and selling activity for Selecta Biosciences
or or view top insider-buying stocks.

How do I buy shares of Selecta Biosciences?

Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Selecta Biosciences' stock price today?

One share of SELB stock can currently be purchased for approximately $3.70.

How much money does Selecta Biosciences make?

Selecta Biosciences has a market capitalization of $399.71 million and generates $6.68 million in revenue each year. The company earns $-55,350,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis.

How many employees does Selecta Biosciences have?

Selecta Biosciences employs 39 workers across the globe.

What is Selecta Biosciences' official website?

The official website for Selecta Biosciences is selectabio.com.

Where are Selecta Biosciences' headquarters?

Selecta Biosciences is headquartered at 65 Grove Street, Watertown MA, 02472.

How can I contact Selecta Biosciences?

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected]

This page was last updated on 3/9/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.